MX2019006600A - Agonistas duales de glp-1/glp-2. - Google Patents

Agonistas duales de glp-1/glp-2.

Info

Publication number
MX2019006600A
MX2019006600A MX2019006600A MX2019006600A MX2019006600A MX 2019006600 A MX2019006600 A MX 2019006600A MX 2019006600 A MX2019006600 A MX 2019006600A MX 2019006600 A MX2019006600 A MX 2019006600A MX 2019006600 A MX2019006600 A MX 2019006600A
Authority
MX
Mexico
Prior art keywords
glp
dual agonists
glucagon
prophylaxis
peptide
Prior art date
Application number
MX2019006600A
Other languages
English (en)
Inventor
Giehm Lise
Due Larsen Bjarne
Vincent Gordon Edwards Alistair
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2019006600A publication Critical patent/MX2019006600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La invención se refiere a compuestos que tienen actividad agonista en los receptores de GLP-1 (péptido 1 tipo glucagón) y GLP-2 (péptido 2 tipo glucagón). Los compuestos encuentran uso, entre otros, en la profilaxis o el tratamiento del daño y disfunción intestinal, regulación del peso corporal, y profilaxis o tratamiento de la disfunción metabólica.
MX2019006600A 2016-12-09 2017-12-11 Agonistas duales de glp-1/glp-2. MX2019006600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600756 2016-12-09
PCT/EP2017/082289 WO2018104560A1 (en) 2016-12-09 2017-12-11 Glp-1/glp-2 dual agonists

Publications (1)

Publication Number Publication Date
MX2019006600A true MX2019006600A (es) 2019-08-01

Family

ID=61007645

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006600A MX2019006600A (es) 2016-12-09 2017-12-11 Agonistas duales de glp-1/glp-2.

Country Status (12)

Country Link
US (1) US11130793B2 (es)
EP (1) EP3551652B1 (es)
JP (1) JP2020500890A (es)
KR (1) KR102587196B1 (es)
CN (1) CN110099922A (es)
AU (1) AU2017373901B2 (es)
BR (1) BR112019011859A2 (es)
CA (1) CA3044915A1 (es)
MX (1) MX2019006600A (es)
RU (1) RU2756011C2 (es)
SA (1) SA519401924B1 (es)
WO (1) WO2018104560A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
WO2020020904A1 (en) * 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
EP4126003A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4294424A1 (en) 2021-02-18 2023-12-27 Zealand Pharma A/S Composition for treating short bowel syndrome
IL311166A (en) * 2021-09-03 2024-04-01 Zealand Pharma As dosage regimen
CN116655772A (zh) * 2022-02-18 2023-08-29 成都奥达生物科技有限公司 一种长效的glp-1/glp-2双激动剂化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
ES2361095T5 (es) * 2005-05-04 2021-11-23 Zealand Pharma As Análogos del péptido 2 tipo glucagón (GLP-2)
CN101331224A (zh) * 2005-10-24 2008-12-24 森托科尔公司 Glp-2模拟体、多肽、组合物、方法和用途
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
DK2454282T3 (en) * 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
US20130157954A1 (en) 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
KR20150006052A (ko) * 2012-05-03 2015-01-15 질랜드 파마 에이/에스 글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
JP2017537894A (ja) * 2014-10-31 2017-12-21 グブラ エーピーエス Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド

Also Published As

Publication number Publication date
EP3551652B1 (en) 2021-01-20
KR20190091334A (ko) 2019-08-05
RU2019121280A3 (es) 2021-02-05
CA3044915A1 (en) 2018-06-14
KR102587196B1 (ko) 2023-10-10
US11130793B2 (en) 2021-09-28
AU2017373901B2 (en) 2021-06-03
RU2019121280A (ru) 2021-01-12
RU2756011C2 (ru) 2021-09-24
JP2020500890A (ja) 2020-01-16
WO2018104560A1 (en) 2018-06-14
BR112019011859A2 (pt) 2019-10-29
CN110099922A (zh) 2019-08-06
EP3551652A1 (en) 2019-10-16
US20190338009A1 (en) 2019-11-07
SA519401924B1 (ar) 2022-11-03
AU2017373901A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX2019006486A (es) Agonistas duales acilados de glp-1/glp-2.
MX2019006600A (es) Agonistas duales de glp-1/glp-2.
IL279300A (en) 1-GLP agonist receptors and their use
IL279224B1 (en) 1-glp agonist receptors and their use
NZ740644A (en) Glucagon receptor agonists
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
PH12020551742A1 (en) Gip derivatives and uses thereof
EA035466B9 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
MX2019006429A (es) Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
PH12017501205A1 (en) Glucagon derivatives
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
MY195657A (en) Liraglutide In Cardiovascular Conditions
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)